Resources

This template is for applications for non-Medicare Benefits Schedule (MBS) funding. You must upload at least one PICO set as part of your application. It will make up most of the information in your application because it describes the population, intervention, comparators and outcomes (PICO).

This template is for applications for Medicare Benefits Schedule (MBS) funding. You must upload at least one PICO set as part of your application. It will make up most of the information in your application because it describes the population, intervention, comparators and outcomes (PICO).

These technical guidelines provide advice to applicants and health technology assessment (HTA) groups on the HTA methods that are used throughout the MSAC assessment pathway.

Applicants can prepare their own assessment report using this template. The 5 sections of the template are context, clinical evaluation, cost-effectiveness analysis or cost-minimisation, use of the health technology in practice, and other relevant information.

Example of an application summary generated by the Health Products Portal (HPP) after an MSAC application form is lodged for non-Medicare Benefits Schedule (MBS) funding.

Example of an application summary generated by the Health Products Portal (HPP) after an MSAC application form is lodged for Medicare Benefits Schedule (MBS) funding.

Example of an application record generated by the Health Products Portal (HPP) after an MSAC application for non-Medicare Benefits Schedule (MBS) funding is lodged. Use this example to understand the information you will need to enter in the HPP application form.

Example of an application record generated by the Health Products Portal (HPP) after an MSAC application for Medicare Benefits Schedule (MBS) funding is lodged. Use this example to understand the information you will need to enter in the HPP application form.

This template contains guidance for health technology assessment (HTA) groups to develop a commentary on an applicant-developed assessment report (ADAR). A commentary should critically appraise the ADAR and identify strengths and weaknesses in the evidence or approach.

If agreed with the applicant, our secretariat can contract a health technology assessment (HTA) group to prepare an assessment report.

This template contains guidance for health technology assessment (HTA) groups to develop a PICO confirmation.

This framework outlines our approach to categorising applications for MSAC. It assists with deciding the suitability of MSAC applications and the assessment pathway for suitable applications. It is based on specific criteria, such as clinical novelty and complexity.

This statement outlines MSAC’s views on the place of programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing to help decide eligibility for PD-(L)1 checkpoint inhibitors.

This is a summary of the MSAC guidelines and their purpose. It helps consumers, carers and other stakeholders understand the technical complexities of the full guidelines and the MSAC assessment process.

You must refer to this framework if you are applying for a new or amended Medicare Benefits Schedule (MBS) item and your proposed MBS item descriptor refers to a specific radiopharmaceutical or a set of radiopharmaceuticals.

This is a summary of the key issues underlying the science, evidence and uncertainties of using microsatellite instability (MSI) testing and immunohistochemical analysis to detect mismatch repair deficiency (dMMR) in cancers.

This paper provides guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer and many other types of tumours, to access pembrolizumab treatment.